1. |
MERLO L M F,GRABLER S,DUHADAWAY J B,et al. Therapeutic antibody targeting of indoleamine-2,3-dioxygenase(IDO2) inhibits autoimmune arthritis[J]. Clin Immunol,2017,179:8-16.
|
2. |
TERNANT D,DUCOURAU E,PERDRIGER A,et al.Relationship between inflammation and infliximab pharmacokinetics in rheumatoid arthritis[J]. Br J Clin Pharmacol,2014,78(1):118-128.
|
3. |
ALETAHA D, NEOGI T, SILMAN A J,et al.2010 Rheumatoid arthritis classification criteria:an American College of Rheumatology/European League Against Rheumatism collaborative initiative[J]. Arthritis Rheum,2010,62(9):2569-2581.
|
4. |
HEEGAARD C,DREYER L,EGSMOSE C,et al.Test-retest reliability of the Disease Activity Score 28 CRP(DAS28-CRP),the Simplified Disease Activity Index(SDAI) and the Clinical Disease Activity Index(CDAI) in rheumatoid arthritis when based on patient self-assessment of tender and swollen joints[J]. Clin Rheumatol,2013,32(10):1493-1500.
|
5. |
PREVOO M L,VAN'T HOF M A,KUPER H H,et al.Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prosepective longitudinal study of patients with rheumatoid arthritis[J]. Arthritis Rheum,1995,38(1):44-48.
|
6. |
杨阳. 基于液相-串联质谱联用技术的靶向氨基酸代谢组学发现结直肠癌诊断的生物标志物[D]. 上海:中国人民解放军海军军医大学,2018.
|
7. |
王祖斌,朱一麟. hUC-MSCs治疗对免疫性血小板减少症患儿的免疫功能、色氨酸代谢通路以及相关基因表达的影响[J]. 海南医学院学报,2016,22(2):193-196.
|
8. |
薛国娟. 吲哚胺2,3-双加氧酶与淋巴瘤关系的研究进展[J]. 肿瘤预防与治疗,2017,30(2):127-130.
|
9. |
ASLIBEKYAN S,BROWN E E,REYNOLDS R J,et al.Genetic variants associated with methotrexate efficacy and toxicity in early rheumatoid arthritis:results from the treatment of early aggressive rheumatoid arthritis trial[J]. Pharmacogenomics J,2014,14(1):48-53.
|
10. |
CHEN J,JUN L,SHIYONG C,et al.Increased TTS expression in patients with rheumatoid arthritis[J]. Clin Exp Med,2015,15(1):25-30.
|
11. |
应伊丽,袁远. IDO/TTS介导的色氨酸代谢途径在免疫性血小板减少症患者发病及治疗中的作用[J]. 中国现代医生,2017,55(36):6-9.
|
12. |
李兆建,刘小倩,徐俊卿,等. 原发免疫性血小板减少症患者大剂量地塞米松治疗前后色氨酸代谢状态[J]. 中华血液学杂志,2017,38(3):222-226.
|
13. |
MERLO L M,MANDIK-NAYAK L.IDO2:a pathogenic mediator of inflammatory autoimmunity[J]. Clin Med Insights Pathol,2016,9(Suppl 1):21-28.
|
14. |
BRUSCA S B,ABRAMSON S B,SCHER J U.Microbiome and mucosal inflammation as extra-articular triggers for rheumatoid arthritis and autoimmunity[J]. Curr Opin Rheumatol,2014,26(1):101-107.
|
15. |
周珺,袁远. IDO/TTS介导的色氨酸代谢途径在免疫性血小板减少症患者发病及治疗中的作用探讨[J]. 中国现代医生,2018,56(17):118-121.
|
16. |
MERLO L M F,GRABLER S,DUHADAWAY J B,et al. Therapeutic antibody targeting of indoleamine-2,3-dioxygenase(IDO2) inhibits autoimmune arthritis[J]. Clin Immunol,2017,179:8-16.
|